[ET Net News Agency, 4 January 2022] HBM Holdings Limited (02142) said the company has
completed the first dosing of first patient in two phase I trials for the treatment of
advanced hepatocellular carcinoma and other solid tumours, as well as the treatment of
advanced neuroendocrine neoplasm and other solid tumours in the clinical trial of HBM4003,
which is the next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb)
developed by the company.
This clinical study aims to assess the safety, tolerability, pharmacokinetics/
pharmacodynamics, and preliminary efficacy of HBM4003 in combination with toripalimab
(PD-1 antibody) in patients with hepatocellular carcinoma, neuroendocrine neoplasm and
other solid tumours in China. (RC)